MAXCYTE, INC. (MXCT) — SEC Financial Statements & Analysis

MAXCYTE, INC. (MXCT) is a services-commercial physical & biological research company, incorporated in DE. MAXCYTE, INC. trades on Nasdaq as: MXCT. MAXCYTE, INC. (MXCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, MAXCYTE, INC. carries a market cap of $131.39M, a P/E ratio of -3.69x, a P/B ratio of 0.83x, a P/S ratio of 4.23x, an enterprise value of $116.35M, and an EV/EBITDA multiple of -3.09x. On profitability, it posts a gross margin of 79.23%, an operating margin of -134.59%, a net margin of -114.77%, a Return on Equity (ROE) of -20.39%, a Return on Assets (ROA) of -17.62%, and a Return on Invested Capital (ROIC) of -26.08%. Per share, it reports EPS of $-0.33, diluted EPS of $-0.33, free cash flow per share of $-0.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -13.15% year-over-year, net income growth of -20.41% year-over-year, and EPS growth of -20.72% year-over-year. On the balance sheet, it maintains a current ratio of 12.26x, a quick ratio of 11.10x, working capital of $111.38M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, free cash flow of $-23.64M (TTM), and net debt of $-15.04M. Figures sourced from SEC EDGAR.

Market Cap

$131.39M

P/E TTM

-3.69x

EPS TTM

$-0.33

P/B TTM

0.83x

ROE TTM

-20.39%

ROA TTM

-17.62%

Debt To Equity

0.16x

Free Cash Flow TTM

$-23.64M

Net Revenue TTM Growth 1Y

-13.15%

Data as of 2026-06-30 · Source: SEC EDGAR